Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000150308 | SCV000197392 | likely benign | not specified | 2013-10-11 | criteria provided, single submitter | clinical testing | Gly2213Ser in Exon 48 of CDH23: This variant is not expected to have clinical s ignificance because the glycine (Gly) residue at position 2213 is not conserved through species, with many mammals having a serine (Ser). In addition, this var iant has been identified in 0.01% (1/8522) of European American chromosomes by t he NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSNP rs37 5900265). |
Labcorp Genetics |
RCV002516020 | SCV003515553 | likely benign | not provided | 2024-11-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004019802 | SCV004922008 | uncertain significance | Inborn genetic diseases | 2024-01-03 | criteria provided, single submitter | clinical testing | The c.6637G>A (p.G2213S) alteration is located in exon 48 (coding exon 47) of the CDH23 gene. This alteration results from a G to A substitution at nucleotide position 6637, causing the glycine (G) at amino acid position 2213 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV002516020 | SCV005437529 | uncertain significance | not provided | 2024-06-13 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |